G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 96
Summary
- Conditions
- Advanced Breast Cancer
- Breast Cancer
- Breast Cancer - Female
- Breast Neoplasm
- Carcinoma, Ductal, Breast
- Metastatic Breast Cancer
- Stage IV Breast Cancer
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03455270
- Collaborators
- Not Provided
- Investigators
- Study Director: Clinical Contact G1 Therapeutics, Inc.